Russell Frank Company’s Esperion Therapeutics ESPR Stock Holding History

Russell Frank Company’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$300K	Buy	17,722 +81	+0.5%	+$1.3K	﹤0.01%	2604
2015 Q4	$402K	Sell	17,641 -53,263	-75%	-$1.34M	﹤0.01%	2544
2015 Q3	$1.67M	Sell	70,904 -14,224	-17%	-$893K	﹤0.01%	1954
2015 Q2	$6.96M	Buy	85,128 +60,617	+247%	+$5.93M	0.01%	1218
2015 Q1	$2.27M	Sell	24,511 -42,746	-64%	-$2.76M	﹤0.01%	1702
2014 Q4	$2.71M	Buy	+67,257	New	+$2.06M	﹤0.01%	1610

Other funds holding ESPR

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Russell Frank Company's ESPR Position: Q1 2016 in Review

Russell Frank Company increased its Esperion Therapeutics (ESPR) stake by 0.46% in Q1 2016, buying an estimated $1.3K and bringing the position to 17,722 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #2604.

Russell Frank Company first reported a position in ESPR in Q4 2014 and has held it in 6 quarters since. The position peaked at $6.96M in Q2 2015. 109 funds tracked by Wall St. Rank hold ESPR as of Q1 2016.

Russell Frank Company held 17,722 shares of Esperion Therapeutics worth $300K as of Q1 2016.
Russell Frank Company bought 81 Esperion Therapeutics shares in Q1 2016, an estimated $1.3K.
Esperion Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2604 holding.
Russell Frank Company first reported a position in Esperion Therapeutics in Q4 2014 and has held it in 6 quarters since.
Russell Frank Company's Esperion Therapeutics position peaked at $6.96M in Q2 2015.
109 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.